Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Prolong Pharmaceuticals, LLC

Home Clinical Trial Sponsors and OrganizationsProlong Pharmaceuticals, LLC

Prolong Pharmaceuticals, LLC

300 Corporate Ct Ste B, South Plainfield, New Jersey, United States

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

4

2 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

3

75.0%

Trial Status Distribution

Active, not recruiting

2

50.0%

Completed

1

25.0%

Recruiting

1

25.0%

Clinical Trials

Trials sponsored by this organization (4)

Study of the efficacy, safety, tolerability and drug blood levlrs of ANF-RHO to treat patients with low white blood cells count

Active, not recruiting

Jul 201710 participants

A randomized and open-label dose-finding, phase 2, efficacy, safety, and pharmacokinetic study of once-per-cycle prophylactic injections of ANF-RHO™ versus pegfilgrastim (Neulasta®) in non-metastatic breast cancer patients at high risk of chemotherapy-induced neutropenia (CIN)

Active, not recruiting

Jan 201765 participants

A Phase 1 Single Blind, Randomized, Single-Dose, Safety, Tolerability, Pharmacodynamic, and Pharmacokinetic Study of ZY7318 (pegylated recombinant human erythropoietin) in Healthy Volunteers

Apr 201332 participants

A phase I double-blind, placebo-controlled, safety, tolerability, pharmacokinetic and pharmacodynamic study of ascending single doses of ANF-Rho in comparison to standard of care-Neulasta® in healthy volunteers

83 participants

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials4
Approvals
News

Back to Organizations